Back to Results

Phase 1b/2, Open-Label Study Evaluating the Safety and Efficacy of KRT-232 in Patients with p53 Wild-Type (p53WT) Merkel Cell Carcinoma (MCC) Who Have Failed Anti-PD-1 or Anti-PD-L1 Immunotherapy, or in Combination with Avelumab in MCC Patients who are Anti-PD-1 or Anti-PD-L1 Treatment Naive

Study category: Cancer

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Type of Study

Treatment

Location

University of Colorado Hospital

Principal Investigator
Karl Lewis,  MD

Karl Lewis, MD

Study ID

Protocol Number: 18-2284

More information available at ClinicalTrials.gov: NCT03787602

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers